RU2515904C2 - Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения - Google Patents

Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения Download PDF

Info

Publication number
RU2515904C2
RU2515904C2 RU2009114682/10A RU2009114682A RU2515904C2 RU 2515904 C2 RU2515904 C2 RU 2515904C2 RU 2009114682/10 A RU2009114682/10 A RU 2009114682/10A RU 2009114682 A RU2009114682 A RU 2009114682A RU 2515904 C2 RU2515904 C2 RU 2515904C2
Authority
RU
Russia
Prior art keywords
antibody
tumor
antibodies
functional fragments
resistant
Prior art date
Application number
RU2009114682/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009114682A (ru
Inventor
Лилиан ГЁТШ
Александра ЖУАННО
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2009114682A publication Critical patent/RU2009114682A/ru
Application granted granted Critical
Publication of RU2515904C2 publication Critical patent/RU2515904C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009114682/10A 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения RU2515904C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
FR06/08514 2006-09-28
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (2)

Publication Number Publication Date
RU2009114682A RU2009114682A (ru) 2010-11-20
RU2515904C2 true RU2515904C2 (ru) 2014-05-20

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009114682/10A RU2515904C2 (ru) 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения

Country Status (21)

Country Link
US (2) US8241646B2 (enExample)
EP (4) EP2491945B9 (enExample)
JP (1) JP5774276B2 (enExample)
KR (1) KR101504770B1 (enExample)
CN (1) CN101516394B (enExample)
AR (1) AR063061A1 (enExample)
AU (1) AU2007312437C1 (enExample)
BR (1) BRPI0717246A2 (enExample)
CA (1) CA2663561A1 (enExample)
FR (1) FR2906533B1 (enExample)
IL (1) IL197790A (enExample)
MA (1) MA30954B1 (enExample)
MX (1) MX2009003245A (enExample)
NO (1) NO20091613L (enExample)
NZ (1) NZ576420A (enExample)
RU (1) RU2515904C2 (enExample)
TN (1) TN2009000102A1 (enExample)
TW (1) TWI516276B (enExample)
UA (1) UA102812C2 (enExample)
WO (1) WO2008046724A1 (enExample)
ZA (1) ZA200902697B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706967C2 (ru) * 2015-04-27 2019-11-21 Пьер Фабр Медикамент Антитело к igf-1r и его применение для диагностики рака
RU2706959C2 (ru) * 2015-04-27 2019-11-21 Пьер Фабр Медикамент Антитело к igf-1r и его применение для диагностики рака
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
RU2734678C2 (ru) * 2015-10-26 2020-10-21 Кетера Лимитед Генетическая конструкция
RU2773317C2 (ru) * 2015-10-13 2022-06-01 Юрека Терапьютикс, Инк. Антительные агенты, специфичные к cd19 человека, и их применения

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
BR112015022123B1 (pt) * 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
CN106794194A (zh) * 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
EP1806364B1 (fr) 2002-01-18 2013-07-31 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
US20050142609A1 (en) * 2003-10-08 2005-06-30 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EFFERTH T. et al., "Antibody-directed therapy of multidrug-resistant tumor cells", Med Oncol Tumor Pharmacother. (1992); 9(1):реферат. РАЕВСКИЙ П. М. "Нецитостатическая терапия злокачественных опухолей (попытка гипотетического рассмотрения)", Рос. хим. ж. (Ж. Рос. хим. об-ва им. Д.И. Менделеева) (2002), 46(3), 90-95 *
TAKASHI TSURUO, "Mechanisms Of Multidrug Resistance And Implications For Therapy", Cancer Science (1988), 79:285-296. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706967C2 (ru) * 2015-04-27 2019-11-21 Пьер Фабр Медикамент Антитело к igf-1r и его применение для диагностики рака
RU2706959C2 (ru) * 2015-04-27 2019-11-21 Пьер Фабр Медикамент Антитело к igf-1r и его применение для диагностики рака
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
RU2773317C2 (ru) * 2015-10-13 2022-06-01 Юрека Терапьютикс, Инк. Антительные агенты, специфичные к cd19 человека, и их применения
RU2734678C2 (ru) * 2015-10-26 2020-10-21 Кетера Лимитед Генетическая конструкция

Also Published As

Publication number Publication date
TW200822934A (en) 2008-06-01
EP2497491B1 (en) 2017-03-01
BRPI0717246A2 (pt) 2013-10-08
KR20090057469A (ko) 2009-06-05
AR063061A1 (es) 2008-12-23
CN101516394B (zh) 2014-07-30
KR101504770B1 (ko) 2015-03-20
IL197790A (en) 2016-10-31
JP2010504743A (ja) 2010-02-18
IL197790A0 (en) 2011-08-01
EP2491945B9 (en) 2017-03-08
US8241646B2 (en) 2012-08-14
EP2494984B1 (en) 2017-01-04
EP2491945B1 (en) 2016-12-07
FR2906533A1 (fr) 2008-04-04
AU2007312437C1 (en) 2014-04-10
US20130028835A1 (en) 2013-01-31
EP2497491A1 (en) 2012-09-12
UA102812C2 (ru) 2013-08-27
WO2008046724A1 (en) 2008-04-24
CA2663561A1 (en) 2008-04-24
EP2494984A1 (en) 2012-09-05
CN101516394A (zh) 2009-08-26
AU2007312437B2 (en) 2014-01-23
US20100146650A1 (en) 2010-06-10
NO20091613L (no) 2009-06-26
EP2081592A1 (en) 2009-07-29
US8808667B2 (en) 2014-08-19
ZA200902697B (en) 2010-04-28
MA30954B1 (fr) 2009-12-01
MX2009003245A (es) 2009-07-07
TN2009000102A1 (en) 2010-08-19
HK1131063A1 (en) 2010-01-15
RU2009114682A (ru) 2010-11-20
FR2906533B1 (fr) 2013-02-22
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
AU2007312437A1 (en) 2008-04-24
EP2081592B1 (en) 2016-01-13
TWI516276B (zh) 2016-01-11
EP2491945A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
RU2515904C2 (ru) Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
JP2021525080A (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
CN101535344B (zh) 新型抗增殖抗体
EP3851455B1 (en) Monoclonal antibody specifically binding human and monkey cd38 antigens, preparation method and use thereof
CN102027014A (zh) 用于治疗癌症的新抗体
EP4453033A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
US20030180799A1 (en) Antibodies against plasma cells
TW202408584A (zh) 抗體-藥物結合物與抗SIRPα抗體之組合
HK1131063B (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170928